SARCOMA ONCOLOGY CENTER

You are here: Home/investigational studies/Clinical Trial

CLINICAL TRIALS AT SARCOMA ONCOLOGY CENTER

	Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
	A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients with Hormone-Refractory Prostate Cancer
	A Phase 1 Dose Escalation Study of the Safety,Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nano-Suspension for Injection Administered Intravenously to Subjects with Solid Tumors
	An Open-Label Phase 1 Study to Investigate the Safety and Maximum Tolerated Dose of INNO-206 (Doxorubicin-6-Maleimidocaproyl hydrazone; DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects with Advanced Solid Tumors
	A Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC)
	A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing locally advanced or metastatic breast cancer
	Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
	A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and Other Patients
	A Phase II study of Amrubicin Chemotherapy as First Line Treatment in Patients with Metastatic or Unresectable Soft Tissue Sarcoma.
	Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma.
	Cardiac repolarization in cancer patients receiving oprelvekin for prevention of severe thrombocytopenia and the reduction or the need for platelet transfusions after myelosuppressive chemotherapy in subjects with nonmyeloid malignancies
	A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung
	A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib in Metastatic GIST Patients With Imitinib Trough Levels Less Than 1100 nanograms/ml
	Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors
	A Phase II Trial of Dasatinib in Advanced Sarcoma
	Paclitaxel in Combination with Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma
	A multinational, randomized, double-blind placebo controlled study of AVE8062 (25 mg/m2) administered every 3 weeks, in patients with advanced-stage soft tissue sarcoma treated with cisplatin (75 mg/m2) after failure of anthracycline and ifosfamide chemotherapies
	An Open-label, Multi-center, Phase 2 Study of Denosumab in subjects with Giant Cell Tumor of Bone
	A Randomized Multicenter Phase III Trial of Trabectedin (Yondelis) versus Doxorubicin based Chemotherapy as First Line Therapy in Patients with Translocation Related Sarcomas (TRS)
	A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
	A Phase I/II Study of VEGF-Antisense Oligonucleoside (VEGF-AS, Veglin) in combiantion with Pemetrexed and Cisplatin for the Treatment of Advanced Malignant mesothelioma
	A Multicenter, Open Label Single arm Study of YONDELIS (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or are Refractory to Standard Care Treatment

If you need more information about Clinical Trials, you can either contact the office or fill in your information here.

For more than 75 years, Certification by the American Board of Internal Medicine (ABIM) has stood for the highest standard in internal medicine and its 19 subspecialties and has meant that internists have demonstrated – to their peers and to the public – that they have the clinical judgment....more
Ridaforolimus in Treatment of Sarcoma-SUCCEED...more
Lazarex Cancer Foundation builds a bridge to hope, dignity and life for cancer patients and their families. We provide financial assistance to defray..more
Caris Life Sciences™ Transforming Healthcare Into Human Care..more